If approved, Gazyva/Gazyvaro would become the first anti-CD20 therapy for SLE, offering a targeted B-cell approach to managing disease activity and progression
For those dealing with alcohol use concerns, resources like Choose Your Horizon offer specialized support that complements metabolic health goals
The amount of insulin I needed kept going up year after year
Natural GLP-1 secretion in the body follows a circadian pattern
Researchers, driven by the quest for small, selective, and membrane-permeable NNMT inhibitors, unearthed the potency of 5-Amino 1MQ
In ATTAIN-1, adverse event-related discontinuation rates were 5.3% with orforglipron 6 mg, 7.6% with 12 mg, and 10.3% with 36 mg, compared with 2.7% with placebo